Nkarta News

HC Wainwright & Co. Reiterates Buy on Nkarta, Maintains $23 Price Target

BenzingaJul 24 15:05 ET · Ratings

Buy Rating Confirmed: Expanding Potential of Nkarta's NKX019 in SLE Treatment

TipRanksJul 24 09:35 ET · Ratings

Express News | Nkarta Has Initiated An Investigator-sponsored Trial Of NKX019, A Cd19-directed Chimeric Antigen Receptor NK-cell Therapy For Systemic Lupus Erythematosus. In June 2024, Nkarta Initiated Ntrust-1 Phase 1 Trial Of NKX019 For Lupus Nephritis

BenzingaJul 24 06:07 ET

Express News | Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating Nkx019 for Systemic Lupus Erythematosus

ReutersJul 24 06:00 ET

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Globe NewswireJul 24 06:00 ET

Sector Update: Health Care Stocks Gain in Afternoon Trading

MT NewswiresJul 16 13:57 ET

Nkarta Shares Rise After Co. Names President and Chief Medical Officer

WSJJul 16 12:33 ET

Express News | Nkarta Shares Are Trading Higher After the Company Appointed Nadir Mahmood as President

BenzingaJul 16 10:54 ET

Express News | Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

ReutersJul 16 06:01 ET

Nkarta (NKTX) Upgraded to Buy: Here's What You Should Know

Yahoo FinanceJul 10 12:00 ET

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Simply Wall StJul 3 11:08 ET

Stifel Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $18

Moomoo NewsJun 28 09:33 ET · Ratings

Express News | Needham Reiterates Buy on Nkarta, Maintains $13 Price Target

BenzingaJun 28 05:28 ET

William Blair Maintains Nkarta(NKTX.US) With Buy Rating

Moomoo NewsJun 27 16:32 ET · Ratings

Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $13

Moomoo NewsJun 27 13:31 ET · Ratings

H.C. Wainwright Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $23

Moomoo NewsJun 27 12:31 ET · Ratings

Express News | Nkarta Initiates Ntrust-1 Of NKX019 In Lupus Nephritis, With First Patient In Screening. FDA Also Clears Second Investigational New Drug Application For NKX019 In Autoimmune Disease

BenzingaJun 27 06:04 ET

Express News | Nkarta Inc: Clinical Data From Ntrust-1 and Ntrust-2 Planned for 2025

ReutersJun 27 06:00 ET

Express News | Nkarta Initiates Clinical Trial of Nkx019 in Lupus Nephritis With First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

ReutersJun 27 06:00 ET

Express News | Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.d., Facr, to Board of Directors

ReutersJun 13 16:01 ET